Real-time molecular cancer imaging
for fluorescence-guided surgery
Why?
A major clinical challenge: the treatment of microscopic abdominal metastases, a frequent consequence of colorectal, gastric, ovarian and pancreatic cancers, which affect more than a million people worldwide every year.
How?
The innovative see2cure protein platform has been designed as a fluorescent targeting tracer. It specifically detects these metastases by recognising its molecular target during fluorescence-guided surgery, whether open (laparotomy) or minimally invasive (laparoscopy). The aim of this technology is to improve surgical results and reduce recurrence, which currently affects 75% of patients. It enables early, targeted detection of lesions that are invisible to the naked eye.
Specific detection at the earliest stages
Intraperitoneal injection
to reach each lesion independently of its vascularization.
Intrinsic specificity for a carcinoma-associated glycan biomarker, the Thomsen-Friedenreich antigen,
expressed by 90% of epithelial cancers (adenocarcinoma) and enabling differentiation between tumour and healthy tissues.
A pan-adenocarcinoma glycosidic biomarker:
Thomsen-Friedenreich (TF) antigen or CD176
Preclinical proof of concept on late stage ovarian cancer
How it works
#1
Intraperitoneal administration of fluorescent surgical tracer
Allows nodules to be detected at a very early stage, before blood circulation becomes established.
#2
Targeting a marker expressed by 90% of carcinoma and invisible in healthy tissue
#3
Real-time visualisation for complete tumour resection
Pipeline
The use of S2C tracer in surgical assistance for ovarian cancers is at the regulatory preclinical stage. As the biomarker detected is pan-adenocarcinoma, we will be able to target all other epithelial cancers expressing it and metastasing within the abdomen at advanced stages (colon, rectum, pancreas, stomach, lungs, breasts).
Image-guided surgery, open or minimal invasive
Ovarian cancer
S2C007
Patent EP24175611
Preclinical
Preclinical
Preclinical
Phase 1
Preclinical
Phase 2
Preclinical
Phase 3
CD176-expressing peritoneal secondary tumors
S2C00x
Preclinical
Preclinical
Preclinical
Phase 1
Preclinical
Phase 2
Preclinical
Phase 3
An immunohistofluorescent test to include patients in clinical trials
In vitro immunohistofluorescent testing of samples taken during diagnostic laparoscopy. Inclusion in clinical trials of patients whose tumours can be identified by the tracer.
